All In Biotech

Drug Trial Radar · NCT07699276

Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin

Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

95

Planned (sponsor's estimate)

Start

Feb 10, 2026

Primary completion

Oct 1, 2027

Study completion Nov 15, 2027

Sponsor

Lead sponsor
Mahidol UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting

Conditions

  • Cancer (Solid Tumors)
  • Vomiting
  • Cisplatin
  • Olanzapine

Interventions

  • dexamethasone sparingDrug

    omit dexamethasone on day 2-4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. complete response rateTime frame: 5 days after receiving chemotherapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Faculty of Medicine Siriraj Hospital, Mahidol University

    Bangkok, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.